This page shows the latest Ascletis news and features for those working in and with pharma, biotech and healthcare.
viral diseases to Ascletis in China, potentially opening up a new revenue stream for the drug. ... Under the terms of the deal, Ascletis has agreed to pay an undisclosed upfront cash fee, plus milestones and royalties on any future sales in return for
Roche has made other investments in China in recent years including a collaboration with Chinese-American biotech company Ascletis to help bring its hepatitis C virus (HCV) therapy danoprevir to market
Many of these are infected with HCV genotype 1b, a strain which has proved "highly responsive" to danoprevir, according to Ascletis. ... Commenting on the link-up with Ascletis, Luke Miels, head of Roche's Asia-Pacific pharma operations, said: "our
More from news
Approximately 2 fully matching, plus 1 partially matching documents found.
The first company to list, Ascletis Pharma Inc, was valued at $2bn when its IPO closed on 1 August. ... While some might have seen Ascletis’ fate as a market correction to the biotech stock hype, further IPOs don’t seem to be falling into line.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...